February 25, 2008 – Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE:PRX) announced that its development partner, Immtech Pharmaceuticals, Inc. (AMEX: IMM) has chosen to discontinue the development program for pafuramidine maleate, an investigative therapy...
...receiving recommendations from the Data Safety Monitoring Board, the Steering Committee for the pneumocystis pneumonia (PCP) study and others, and in consultation with the US Food and Drug Administration (FDA) and Immtech’s licensing partners, including Strativa, Immtech has chosen to discontinue the development program for pafuramidine... Par Pharmaceutical's Press Release-
